Skip to main content
Infection and Drug Resistance logoLink to Infection and Drug Resistance
. 2026 Nov 7;19:638117. doi: 10.2147/IDR.S638117

Clinical Outcomes of Trimethoprim-Sulfamethoxazole with or Without Adjunctive Caspofungin in Patients with Moderate-to-Severe HIV-Associated Pneumocystis jirovecii Pneumonia: A Retrospective Cohort Study

Yu Wang 1, Caopei Zheng 1, Yuqing Sun 1, Yulin Zhang 1,2,3,✉
PMCID: PMC13755821  PMID: 43022490

Abstract

Purpose

To evaluate clinical outcomes of trimethoprim-sulfamethoxazole (TMP-SMX) with or without adjunctive caspofungin in patients with moderate-to-severe human immunodeficiency virus (HIV)-associated Pneumocystis jirovecii pneumonia (PJP), and explore factors associated with poor outcomes.

Patients and Methods

Patients with HIV-associated PJP admitted to Beijing Youan Hospital from July 2020 to June 2026 were retrospectively included. Moderate-to-severe PJP was defined as arterial partial pressure of oxygen <70 mmHg or alveolar-arterial oxygen gradient ≥35 mmHg on room air. Patients were grouped by regimen: TMP-SMX monotherapy or TMP-SMX plus caspofungin. The primary outcome was a composite of poor outcomes, including in-hospital death or discharge against medical advice due to poor prognosis. Between-group comparisons, a clinically specified multivariable logistic regression model, and a stabilized inverse probability of treatment weighting (IPTW) sensitivity analysis were performed.

Results

Among 673 screened patients, 155 with moderate-to-severe HIV-associated PJP were analyzed after excluding mild cases and those with incomplete data; 78 received TMP-SMX monotherapy and 77 received TMP-SMX plus caspofungin. The combination group had longer hospital stays (P = 0.003) and higher procalcitonin levels (P = 0.044). Poor outcomes did not differ significantly between groups (P = 0.129). In the primary multivariable model adjusted for PaO2 on room air and C-reactive protein (CRP), adjunctive caspofungin was not significantly associated with poor outcome (adjusted odds ratio [aOR] = 1.603, 95% confidence interval [CI]: 0.654–3.925, P = 0.302). Lower PaO2 (aOR = 0.958, 95% CI: 0.921–0.996, P = 0.032) and higher CRP (aOR = 1.009, 95% CI: 1.000–1.019, P = 0.047) were associated with poor outcome. The IPTW sensitivity analysis likewise showed no statistically significant association between adjunctive caspofungin and poor outcome (weighted OR = 1.939, 95% CI: 0.790–4.763, P = 0.148).

Conclusion

In this retrospective cohort, no statistically significant association was detected between TMP-SMX plus adjunctive caspofungin and poor outcomes in patients with moderate-to-severe HIV-associated PJP. Lower PaO2 and higher CRP were associated with poor outcome in an exploratory adjusted analysis. Larger prospective multicenter studies are needed to clarify the role of adjunctive caspofungin.

Keywords: human immunodeficiency virus, Pneumocystis jirovecii pneumonia, trimethoprim-sulfamethoxazole, caspofungin, poor outcome

Introduction

Pneumocystis jirovecii pneumonia (PJP) is an important opportunistic pulmonary infection in individuals with human immunodeficiency virus (HIV). Although the widespread use of antiretroviral therapy (ART) and PJP prophylaxis has led to a sustained decline in its incidence, PJP remains clinically relevant among patients with HIV with low CD4+ T-cell count, poor ART adherence, or no prior ART exposure.1,2 HIV-associated PJP usually has a subacute onset and may present with progressive dyspnea, fever, dry cough, chest tightness, and gradually worsening respiratory symptoms.3 Some patients already have marked oxygenation impairment at admission, and severe cases may progress to acute respiratory failure requiring intensive care unit (ICU) management.4 Although the overall mortality of HIV-associated PJP has declined in the ART era, patients with moderate-to-severe disease still face a considerable risk of death. A previous Cochrane systematic review showed that mortality during the initial episode of PJP in patients with HIV-associated PJP was approximately 10%-20%, with a further increase in mortality among those requiring mechanical ventilation. Among hypoxemic adults with moderate-to-severe HIV-associated PJP, the 1-month mortality risk was approximately 24.7% in those who did not receive adjunctive corticosteroids and remained approximately 13.8% even among those who did receive adjunctive corticosteroids.5 Therefore, for patients with moderate-to-severe or severe disease, early identification of high-risk cases and optimization of anti-PJP treatment strategies are key clinical issues for improving prognosis.

Trimethoprim-sulfamethoxazole (TMP-SMX) remains the first-line therapy for HIV-associated PJP.6 It exerts anti-P. jirovecii activity by targeting dihydrofolate reductase and dihydropteroate synthase in the folate biosynthesis pathway of P. jirovecii.7 However, in clinical practice, patients with HIV-associated PJP may still be at risk of poor outcomes or treatment limitations despite receiving standard-dose TMP-SMX, owing to factors such as oxygenation impairment at admission, enhanced inflammatory response, hypoalbuminemia, and TMP-SMX-related adverse reactions.8,9 Although caspofungin is generally well tolerated, its addition to high-dose TMP-SMX warrants monitoring for hepatic adverse effects and caspofungin-related infusion reactions, as well as TMP-SMX-associated electrolyte abnormalities.10,11 In severe PJP, disease progression is not only related to impaired clearance of P. jirovecii, but is also closely associated with exaggerated host inflammatory responses, impaired pulmonary function, and hypoxemia.12 Therefore, exploring more rational combination anti-PJP regimens based on TMP-SMX is of important clinical significance.

Caspofungin is an echinocandin antifungal agent that affects fungal cell wall structure by inhibiting β-1,3-glucan synthesis.13 Because cystic forms of P. jirovecii contain β-1,3-D-glucan in their cell wall, whereas the trophic form is relatively insensitive to echinocandins, caspofungin may be more suitable as a combination option with agents such as TMP-SMX that are active against trophic forms, rather than as a substitute for TMP-SMX.13,14 Previous studies have suggested that TMP-SMX combined with caspofungin may have therapeutic value in some patients with PJP, particularly in those with more severe disease or poor response to conventional therapy.15,16 However, existing findings remain inconsistent. This inconsistency may partly reflect methodological limitations of the available evidence, including predominantly retrospective designs, heterogeneous patient populations, and differences in disease severity and treatment timing across studies.15–17 A multicenter observational study did not find a significant advantage of TMP-SMX plus caspofungin over TMP-SMX monotherapy in terms of overall treatment effectiveness or survival outcomes.17 In addition, caspofungin has been evaluated as both first-line combination therapy and salvage therapy, which may complicate direct comparisons across studies.16,17 Thus, the clinical value of caspofungin combination therapy may be influenced by HIV status, disease severity, host inflammatory response, baseline organ function, and timing of administration. Its role in patients with moderate-to-severe HIV-associated PJP therefore requires further clarification.

Against this background, the present retrospective cohort study compared the clinical characteristics and in-hospital outcomes of patients with moderate-to-severe HIV-associated PJP who received TMP-SMX monotherapy with those who received TMP-SMX plus caspofungin. Because treatment allocation and timing were determined by the treating physicians, the observed differences were interpreted as associations and not as causal treatment effects. We examined the association between adjunctive caspofungin use and poor in-hospital outcomes and explored factors associated with poor outcomes in the overall cohort. The analyses were intended to provide clinical evidence for treatment evaluation and prognostic assessment, rather than to establish the efficacy or lack of efficacy of caspofungin.

Materials and Methods

Study Population

All consecutive patients admitted with HIV-associated PJP to Beijing Youan Hospital between July 2020 and June 2026 were screened for eligibility. The six-year study period was selected to include an adequate number of eligible patients for this retrospective cohort. No major changes occurred in diagnostic procedures, standard anti-PJP treatment protocols, or supportive care practices during the study period. The inclusion criteria were as follows: (I) age ≥18 years; (II) confirmed HIV infection and meeting the diagnostic criteria for acquired immunodeficiency syndrome (AIDS) according to the United States Centers for Disease Control and Prevention guidelines,18 defined as a CD4+ T-cell count <200 cells/μL or documentation of at least one AIDS-defining condition; and (III) diagnosis of PJP based on the criteria proposed by the United States Department of Health and Human Services (DHHS) Panel on Opportunistic Infections in Adults and Adolescents.19 These criteria included an immunocompromised status, most commonly a CD4+ T-cell count <200 cells/μL; subacute onset of progressive dyspnea, fever, dry cough, and chest discomfort, with symptoms progressing over several days to weeks; hypoxemia; elevated serum β-1,3-D-glucan and lactate dehydrogenase (LDH) levels, chest imaging showing bilateral symmetrical interstitial infiltrates, sometimes with a perihilar bat-wing distribution, although imaging may be normal in the early stage; microbiological confirmation by detection of P. jirovecii in lung tissue, bronchoalveolar lavage fluid, or induced sputum; or amplification of P. jirovecii DNA by polymerase chain reaction from bronchoalveolar lavage fluid or induced sputum. PJP was diagnosed by the treating physicians according to the DHHS criteria described above, based on the patients’ clinical presentation, imaging, laboratory findings, and microbiological test results when available.

Disease severity was assessed using the alveolar-arterial oxygen tension gradient (A-aDO2) or arterial partial pressure of oxygen (PaO2) while breathing room air. According to the DHHS definition of moderate-to-severe PJP,19 patients with PaO2 <70 mmHg or A-aDO2 ≥35 mmHg were classified as having moderate-to-severe disease, whereas the remaining patients were classified as having mild disease. The exclusion criteria were mild PJP, age <18 years, pregnancy or lactation, and clinically diagnosed concomitant pulmonary infection caused by bacteria, viruses, mycobacteria, or other fungi, based on the clinical, radiologic, and microbiological findings documented in the medical records.

Data Collection

Data were retrospectively collected from the electronic medical record system, including demographic characteristics, comorbidities, smoking history, vital signs, clinical symptoms, treatment-related information, laboratory findings, and clinical outcomes. Demographic, clinical, and laboratory variables used for baseline comparisons were collected at hospital admission. Adjunctive corticosteroid therapy at treatment initiation was recorded as a baseline treatment variable. Treatment-related and clinical-course variables collected during hospitalization included caspofungin combination therapy, length of hospital stay, and clinical outcomes. Among patients receiving caspofungin, the interval from TMP-SMX initiation to caspofungin initiation was recorded. Demographic and clinical variables included age, sex, cardiovascular disease, malnutrition, liver disease, smoking history, pulse, respiratory rate, systolic blood pressure, diastolic blood pressure, fever, cough, and dyspnea. Laboratory findings included white blood cell count, neutrophil count, lymphocyte count, hemoglobin, platelet count, alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin, albumin, creatinine, urea, estimated glomerular filtration rate, serum potassium, serum sodium, serum chloride, C-reactive protein (CRP), procalcitonin (PCT), LDH, erythrocyte sedimentation rate (ESR), CD4+ T-cell count, and serum β-1,3-D-glucan level.

TMP-SMX was administered orally. Each TMP-SMX tablet contained 80 mg of trimethoprim and 400 mg of sulfamethoxazole. The initial dosage, administration frequency, and subsequent dose adjustments of TMP-SMX were individualized by the treating physicians according to patients’ clinical condition and were not analyzed as standardized exposure variables in this retrospective study. Patients were classified according to whether they received caspofungin combination therapy. Patients treated with TMP-SMX without caspofungin were assigned to the no-caspofungin group, whereas those treated with TMP-SMX plus caspofungin were assigned to the caspofungin group. Patients receiving adjunctive caspofungin were administered a 70-mg loading dose followed by 50 mg intravenously once daily. Treatment decisions, including the initiation and timing of adjunctive caspofungin, were made by the treating physicians according to their clinical judgment. Clinical outcomes were assessed during the index hospitalization through hospital discharge. The primary outcome was a composite of poor outcomes, defined as in-hospital death or discharge against medical advice due to poor prognosis. Patients who did not experience either component of the composite outcome and were discharged after clinical improvement were classified as having a favorable outcome.

Statistical Analysis

Normality of continuous variables was assessed within each group using the Shapiro–Wilk test. Normally distributed continuous variables are presented as mean ± standard deviation and were compared between groups using the independent-samples t test. Non-normally distributed continuous variables are presented as median with interquartile range and were compared using the Mann–Whitney U-test. Categorical variables are presented as numbers and percentages and were compared using Pearson’s chi-square test. Fisher’s exact test was used when the expected frequencies were small. The individual components of the composite outcome, in-hospital death and discharge against medical advice due to poor prognosis, were compared between treatment groups using Fisher’s exact tests. Given the limited number of component events, no adjusted component-specific models were fitted. All tests were two-sided, and P < 0.05 was considered statistically significant.

Univariate logistic regression analyses were conducted separately for each predictor. Each univariate model included one predictor, and observations with missing values for that predictor or the outcome were excluded from that model. The primary multivariable model included caspofungin combination therapy as the exposure of interest, PaO2 on room air as an oxygenation measure, and C-reactive protein (CRP) as an inflammatory marker. Covariates were selected on clinical considerations and were not selected on the basis of univariate P values alone. Because the number of poor-outcome events was limited, multivariable analyses were considered exploratory. Multicollinearity among predictors in the primary model was assessed using the variance inflation factor (VIF). An exploratory sensitivity analysis using stabilized inverse probability of treatment weighting (IPTW) was conducted to assess the robustness of the association between caspofungin combination therapy and poor outcome after adjustment for measured baseline covariates. The propensity score was estimated using age, sex, PaO2 on room air, CRP, β-1,3-D-glucan, and CD4+ T-cell count. These covariates were selected to represent demographic, oxygenation/severity, inflammatory/infection, and HIV-related immune-status domains. Propensity scores were truncated at 0.01 and 0.99, and stabilized weights were calculated using the marginal treatment prevalence. The weighted association between caspofungin combination therapy and poor outcome was estimated using a weighted logistic regression model with robust standard errors. Covariate balance before and after weighting was assessed using standardized mean differences. As this analysis could account only for measured covariates, residual or unmeasured confounding may remain. Model discrimination was summarized using the apparent area under the receiver operating characteristic curve (AUC), and model fit was assessed using the Hosmer–Lemeshow goodness-of-fit test. These measures were treated as descriptive, in-sample diagnostics. A nonsignificant Hosmer–Lemeshow test was not interpreted as proof of good calibration, and the apparent AUC was not considered evidence of model validation. Results of multivariable logistic regression are presented as adjusted odds ratios with 95% confidence intervals.

Results

Patient Screening and Grouping

Between July 2020 and June 2026, a total of 673 patients with HIV-associated PJP were screened. After excluding 329 patients with mild PJP and 189 patients with incomplete clinical data, 155 patients with moderate-to-severe HIV-associated PJP were finally included in the analysis. Among the 189 patients with incomplete clinical data, data for most laboratory parameters were unavailable in 82 patients, and room-air PaO2 and/or A-aDO2 measurements required for severity classification were unavailable in 137 patients. These categories overlapped. Among the 155 patients with HIV-associated PJP, 74 had microbiological evidence of PJP, while the remaining 81 were clinically diagnosed based on compatible clinical presentation, imaging, and laboratory findings, without microbiological confirmation. By treatment group, 78 patients received TMP-SMX without caspofungin, whereas 77 received TMP-SMX plus caspofungin. In the no-caspofungin group, 68 patients had a favorable outcome and 10 experienced poor outcomes, including 6 in-hospital deaths and 4 discharges against medical advice due to poor prognosis. In the caspofungin group, 60 patients had a favorable outcome and 17 experienced poor outcomes, including 8 in-hospital deaths and 9 discharges against medical advice due to poor prognosis (Figure 1).

Figure 1.

A flowchart of patient selection and outcomes for no caspofungin and caspofungin groups.

Flowchart of patient selection.

Comparison of Baseline Characteristics and in-Hospital Outcomes Between Treatment Groups

There were no statistically significant differences between the two groups in age, sex distribution, or major comorbidities. Regarding baseline characteristics, cardiovascular disease, malnutrition, liver disease, and smoking history did not differ significantly between groups. In terms of clinical symptoms, the proportions of patients with fever, cough, dyspnea, and those receiving corticosteroid therapy were also comparable between groups. No significant differences were observed in vital signs, including pulse, respiratory rate, systolic blood pressure, and diastolic blood pressure. Among patients receiving caspofungin, the median interval from TMP-SMX initiation to caspofungin initiation was 0 days (interquartile range, 0–0 days; range, 0–27 days) (Table 1). Among laboratory findings, PCT levels were higher in the caspofungin group than in the no-caspofungin group (P = 0.044). Other laboratory findings, including white blood cell count, neutrophil count, lymphocyte count, hemoglobin, platelet count, ALT, AST, total bilirubin, albumin, creatinine, urea, estimated glomerular filtration rate, serum potassium, serum sodium, serum chloride, CRP, LDH, ESR, CD4+ T-cell count, and serum β-1,3-D-glucan level, showed no statistically significant differences between the two groups (Table 1).

Table 1.

Baseline Characteristics by Caspofungin Combination Therapy

Characteristics No Caspofungin (n=78) Caspofungin (n=77) P value
Age, years 42.50 (32.75–54.00) 41.00 (35.00–52.00) 0.905
Sex, male, n (%) 75 (96.15%) 68 (88.31%) 0.068
Comorbidities
 Cardiovascular disease, n (%) 10 (12.82%) 14 (18.18%) 0.356
 Malnutrition, n (%) 10 (12.82%) 8 (10.39%) 0.637
 Liver disease, n (%) 4 (5.13%) 10 (12.99%) 0.088
 Smoking history, n (%) 20 (25.64%) 15 (19.48%) 0.359
Vital signs
 Pulse, beats/min 98.40 ± 17.22 99.56 ± 16.18 0.666
 Respiratory rate, breaths/min 21.00 (20.00–24.00) 21.00 (20.00–24.00) 0.557
 Systolic blood pressure, mmHg 117.00 (105.75–128.00) 120.00 (106.50–128.00) 0.396
 Diastolic blood pressure, mmHg 76.05 ± 9.13 75.58 ± 10.61 0.769
Clinical symptoms and treatment
 Fever, n (%) 49 (62.82%) 53 (68.83%) 0.430
 Cough, n (%) 51 (65.38%) 47 (61.04%) 0.575
 Dyspnea, n (%) 65 (83.33%) 65 (84.42%) 0.855
 Adjunctive corticosteroid therapy at treatment initiation, n (%) 71 (91.03%) 75 (97.40%) 0.167
Treatment timing
 Time from TMP-SMX initiation to caspofungin initiation, days,  median (IQR), range Not applicable 0.00 (0.00–0.00), range 0–27 (n=77)
Oxygenation severity
 PaO2 on room air, mmHg 66.80 (56.30–70.92) 64.80 (55.15–71.45) 0.730
 A-aDO2 on room air, mmHg 46.00 (41.98–54.02) 47.60 (40.68–60.15) 0.433
Laboratory findings
 White blood cell count, ×109/L 6.58 (4.51–9.06) 7.10 (5.29–10.52) 0.188
 Neutrophil count, ×109/L 5.06 (3.09–7.19) 5.86 (3.75–8.69) 0.072
 Lymphocyte count, ×109/L 0.80 (0.48–1.12) 0.66 (0.36–1.04) 0.361
 Hemoglobin, g/L 124.00 (104.75–133.00) 121.00 (104.50–133.50) 0.903
 Platelet count, ×109/L 253.50 (190.75–319.00) 250.00 (189.00–306.50) 0.698
 Alanine aminotransferase (ALT), U/L 25.50 (15.75–42.25) 27.00 (18.00–42.50) 0.481
 Aspartate aminotransferase (AST), U/L 39.00 (27.75–56.25) 41.00 (28.50–56.00) 0.454
 Total bilirubin, μmol/L 8.25 (5.95–10.50) 8.50 (5.75–12.05) 0.823
 Albumin, g/L 29.46 ± 6.40 28.73 ± 6.80 0.497
 Creatinine, μmol/L 61.00 (51.75–76.00) 61.00 (52.00–72.00) 0.624
 Urea, mmol/L 5.10 (4.32–6.99) 5.34 (3.74–7.49) 1.000
 Estimated glomerular filtration rate, mL/min/1.73 m2 114.50 (102.35–129.25) 114.60 (104.10–128.25) 0.926
 Serum potassium, mmol/L 4.05 ± 0.59 4.00 ± 0.60 0.574
 Serum sodium, mmol/L 136.00 (133.80–138.03) 136.00 (133.10–139.60) 0.671
 Serum chloride, mmol/L 100.64 ± 3.95 101.30 ± 4.65 0.346
 C-reactive protein (CRP), mg/L 36.06 (16.94–71.18) 49.92 (22.52–82.27) 0.142
 Procalcitonin (PCT), ng/mL 0.07 (0.05–0.12) 0.09 (0.05–0.39) 0.044
 Lactate dehydrogenase (LDH), U/L 400.00 (296.25–565.75) 422.00 (276.50–659.00) 0.667
 Erythrocyte sedimentation rate (ESR), mm/h 66.85 ± 25.27 64.60 ± 23.48 0.592
 CD4+ T-cell count, cells/μL 21.00 (6.00–41.00) 16.00 (7.00–40.00) 0.809
 β-1,3-D-glucan, pg/mL 145.47 (48.33–243.10) 135.30 (52.30–206.90) 0.697

Notes: Values are presented as mean ± SD, median (IQR), or n (%), as appropriate. The treatment-timing row is reported for caspofungin-treated patients only and describes the interval from TMP-SMX initiation to caspofungin initiation.

Abbreviations: SD, standard deviation; IQR, interquartile range; TMP-SMX, trimethoprim-sulfamethoxazole; PaO2, partial pressure of oxygen; A-aDO2, alveolar-arterial oxygen tension gradient; WBC, white blood cell; ALT, alanine aminotransferase; AST, aspartate aminotransferase; eGFR, estimated glomerular filtration rate; CRP, C-reactive protein; PCT, procalcitonin; LDH, lactate dehydrogenase; ESR, erythrocyte sedimentation rate.

With respect to in-hospital outcomes, length of hospital stay was longer in the caspofungin group than in the no-caspofungin group (P = 0.003), whereas composite poor outcome did not differ significantly between groups (P = 0.129). In-hospital death (P = 0.588) and discharge against medical advice due to poor prognosis (P = 0.159) also did not differ significantly between groups (Table 2).

Table 2.

In-Hospital Clinical Outcomes by Caspofungin Combination Therapy

Clinical Outcome No Caspofungin (n=78) Caspofungin (n=77) P value
Length of hospital stay, days, median (IQR) 16.00 (13.00–20.25) 20.00 (15.00–29.50) 0.003
Composite poor outcome, n (%) 10 (12.82%) 17 (22.08%) 0.129
In-hospital death, n (%) 6 (7.69%) 8 (10.39%) 0.588
Discharge against medical advice due to poor prognosis, n (%) 4 (5.13%) 9 (11.69%) 0.159

Notes: Poor outcome was defined as in-hospital death or discharge against medical advice due to poor prognosis. The two components are also shown separately.

Abbreviation: IQR, interquartile range.

Logistic Regression Analysis of Factors Associated with Poor Outcomes in the Overall Cohort

In univariate logistic regression analyses, lower PaO2 on room air (OR = 0.958, 95% CI: 0.920–0.996, P = 0.032), cardiovascular disease (OR = 4.790, 95% CI: 1.837–12.488, P = 0.001), and higher neutrophil count (OR = 1.117, 95% CI: 1.013–1.232, P = 0.027), ALT (OR = 1.009, 95% CI: 1.002–1.015, P = 0.009), urea (OR = 1.159, 95% CI: 1.037–1.296, P = 0.009), CRP (OR = 1.010, 95% CI: 1.001–1.018, P = 0.026), and LDH (OR = 1.004, 95% CI: 1.002–1.007, P < 0.001) were associated with higher odds of poor outcome. Higher platelet count (OR = 0.994, 95% CI: 0.990–0.999, P = 0.025), albumin (OR = 0.874, 95% CI: 0.808–0.944, P < 0.001), ESR (OR = 0.982, 95% CI: 0.964–0.999, P = 0.043), and CD4+ T-cell count (OR = 0.971, 95% CI: 0.946–0.998, P = 0.034) were associated with lower odds of poor outcome. AST (OR = 1.003, 95% CI: 1.000–1.005, P = 0.059) and serum chloride (OR = 1.090, 95% CI: 0.989–1.202, P = 0.084) were not significantly associated with poor outcome. Caspofungin combination therapy was also not significantly associated with poor outcome (OR = 1.927, 95% CI: 0.820–4.529, P = 0.133). In the primary multivariable model including caspofungin combination therapy, PaO2 on room air, and CRP, caspofungin combination therapy was not significantly associated with poor outcome (adjusted odds ratio [aOR] = 1.603, 95% CI: 0.654–3.925, P = 0.302). Lower PaO2 on room air remained associated with poor outcome (aOR = 0.958, 95% CI: 0.921–0.996, P = 0.032), and higher CRP was also associated with poor outcome (aOR = 1.009, 95% CI: 1.000–1.019, P = 0.047). The apparent AUC was 0.689, the Hosmer–Lemeshow statistic was χ2 = 3.392 (P = 0.907), and the maximum VIF was 1.036. The primary model included 155 complete cases and 27 poor-outcome events for three predictors, corresponding to 9.0 events per predictor. Given the limited number of poor-outcome events, the adjusted analyses were exploratory (Table 3).

Table 3.

Univariate and Multivariable Logistic Regression Analysis of Poor Outcome

Predictor Univariate Analysis Primary Multivariable Model
OR 95% CI P value aOR 95% CI P value
Caspofungin combination therapy 1.927 0.820–4.529 0.133 1.603 0.654–3.925 0.302
PaO2 on room air, mmHg 0.958 0.920–0.996 0.032 0.958 0.921–0.996 0.032
Cardiovascular disease, n (%) 4.790 1.837–12.488 0.001 — — —
Neutrophil count, ×109/L 1.117 1.013–1.232 0.027 — — —
Platelet count, ×109/L 0.994 0.990–0.999 0.025 — — —
Alanine aminotransferase, U/L 1.009 1.002–1.015 0.009 — — —
Aspartate aminotransferase, U/L 1.003 1.000–1.005 0.059 — — —
Albumin, g/L 0.874 0.808–0.944 <0.001 — — —
Urea, mmol/L 1.159 1.037–1.296 0.009 — — —
Serum chloride, mmol/L 1.090 0.989–1.202 0.084 — — —
C-reactive protein (CRP), mg/L 1.010 1.001–1.018 0.026 1.009 1.000–1.019 0.047
Lactate dehydrogenase (LDH), U/L 1.004 1.002–1.007 <0.001 — — —
Erythrocyte sedimentation rate, mm/h 0.982 0.964–0.999 0.043 — — —
CD4+ T-cell count, cells/μL 0.971 0.946–0.998 0.034 — — —

Notes: Each univariate logistic regression included one predictor. Rows are shown for variables with univariate P < 0.10, together with caspofungin (the primary exposure), PaO2, and CRP (the clinically selected adjustment variables). Univariate P values were not used alone to select the primary model covariates. For the primary model, apparent AUC was 0.689, the Hosmer–Lemeshow statistic was χ2 =3.392 (P = 0.907), and the maximum VIF was 1.036. AUC and Hosmer–Lemeshow results are apparent in-sample diagnostics and do not constitute external validation. ORs for continuous variables are per one-unit increase.

Abbreviations: OR, odds ratio; aOR, adjusted odds ratio; CI, confidence interval; PaO2, partial pressure of oxygen; CRP, C-reactive protein; AUC, area under the receiver operating characteristic curve; VIF, variance inflation factor.

Stabilized IPTW Sensitivity Analysis

In the stabilized IPTW sensitivity analysis, caspofungin combination therapy was not significantly associated with poor outcome (weighted OR = 1.939, 95% CI: 0.790–4.763, P = 0.148) (Table 4).

Table 4.

Sensitivity Analyses of Poor Outcomes

Analysis Comparison Weighted OR (95% CI) P value
Stabilized IPTW sensitivity analysis Caspofungin vs no caspofungin 1.939 (0.790–4.763) 0.148

Notes: The IPTW row reports the weighted odds ratio for poor outcome comparing caspofungin combination therapy with no caspofungin.

Abbreviations: IPTW, inverse probability of treatment weighting; OR, odds ratio; CI, confidence interval.

Covariate Balance Before and After IPTW

Before weighting, the largest absolute standardized mean differences were observed for CRP (0.351), sex (−0.303), and CD4+ T-cell count (0.104). After IPTW, all six propensity-score covariates had absolute standardized mean differences below 0.10, indicating improved balance in the measured covariates (Table 5).

Table 5.

Covariate Balance Before and After IPTW

Covariate Unweighted SMD IPTW-Weighted SMD
Age, years −0.034 0.010
Sex, male, n (%) −0.303 −0.049
PaO2 on room air, mmHg 0.096 0.026
C-reactive protein (CRP), mg/L 0.351 0.067
β-1,3-D-glucan, pg/mL −0.051 −0.005
CD4+ T-cell count, cells/μL 0.104 0.051

Notes: Standardized mean differences (SMDs) are shown before and after IPTW. Values closer to zero indicate better balance. An absolute SMD <0.10 is commonly used as a rule-of-thumb benchmark. All six weighted SMDs are below 0.10 in absolute value for the measured covariates shown. The propensity score included age, sex, PaO2, CRP, β-1,3-D-glucan, and CD4+ T-cell count. These variables were chosen for this revised sensitivity analysis to represent demographic, oxygenation/severity, inflammatory/infection, and HIV-related immune-status domains, rather than selected by univariate P values. They are potential proxies for confounding, not documented reasons for prescribing caspofungin. Balance on these measured variables does not exclude unmeasured confounding.

Abbreviations: SMD, standardized mean difference; IPTW, inverse probability of treatment weighting; CRP, C-reactive protein; PaO2, partial pressure of oxygen.

Discussion

Based on a real-world inpatient cohort, this study retrospectively evaluated the clinical outcomes of adding caspofungin to TMP-SMX therapy in patients with moderate-to-severe HIV-associated PJP, and explored factors associated with poor outcomes. The results showed that, compared with the no-caspofungin group, patients in the caspofungin group had no significant differences in age, sex, major comorbidities, clinical symptoms, vital signs, or most laboratory findings. However, patients in the caspofungin group had a longer length of hospital stay and higher PCT levels. The incidence of poor outcomes did not differ significantly between the two groups. In the primary multivariable model adjusted for PaO2 on room air and CRP, caspofungin combination therapy was not significantly associated with poor outcome. Lower PaO2 on room air and higher CRP were associated with poor outcome in this exploratory model.

In this study, caspofungin combination therapy was not significantly associated with poor outcome after multivariable adjustment. This finding was consistent with the stabilized IPTW sensitivity analysis, which also showed no significant association between caspofungin combination therapy and poor outcome (weighted OR = 1.939, 95% CI: 0.790–4.763, P = 0.148). In patients with moderate-to-severe HIV-associated PJP, clinical severity and outcomes may be influenced by multiple factors, including the background of immunosuppression, oxygenation impairment, and organ function status.20 Therefore, the absence of an independent protective association with caspofungin combination therapy does not necessarily indicate a lack of anti-P. jirovecii activity. In real-world clinical practice, caspofungin has been investigated as a first-line combination therapy for moderate-to-severe HIV-associated PJP and has also been used as salvage therapy when TMP-SMX is not tolerated or when standard therapy is contraindicated or limited.16,17,21 Differences between the present study and previous reports suggesting a benefit of adjunctive caspofungin may reflect variation in patient populations, HIV status, disease severity, treatment indications, the timing of caspofungin initiation, and the use of initial combination therapy or salvage therapy.16,17,21 Because the timing of caspofungin initiation in these studies may have been influenced by physician judgment, patient condition, and treatment response, indication bias and unmeasured confounding cannot be excluded. In the present study, although most baseline variables were comparable between the two groups, higher PCT levels were observed in the caspofungin group and may reflect differences in clinical status and treatment decision-making. Although a longer length of hospital stay was also observed in the caspofungin group, it is a post-treatment outcome and cannot be considered evidence of greater baseline disease severity. These findings nevertheless underscore the potential for indication bias and residual confounding in this retrospective cohort. The recorded treatment timing further illustrates this heterogeneity. Although the median interval from TMP-SMX initiation to caspofungin initiation was 0 days, the observed range extended to 27 days. Thus, the caspofungin group likely included patients who received caspofungin at different stages of their clinical course. Patients who received caspofungin later may have had persistent symptoms, inadequate early response, or evolving clinical concerns. This heterogeneity in treatment timing may have influenced the association between adjunctive caspofungin and outcome.

The associations of lower PaO2 on room air and higher CRP with poor outcome are clinically plausible. Lower PaO2 reflects more severe impairment of gas exchange and was independently associated with death in a previous cohort of patients with HIV-associated PJP.22 In a separate cohort of patients with HIV-associated PJP, higher admission CRP, a nonspecific marker of systemic inflammation and tissue damage, was associated with lower PaO2 and death.23 However, because PaO2 and CRP were evaluated in an exploratory model with a limited number of events, these findings should be interpreted as associations rather than definitive prognostic markers.

This study has several limitations. First, as a single-center retrospective study with nonrandom treatment allocation, it remained susceptible to indication bias and residual confounding. A stabilized inverse probability of treatment weighting sensitivity analysis was performed. However, this analysis could adjust only for measured baseline covariates, and residual or unmeasured confounding may remain. Second, oxygen requirement, ICU admission, invasive mechanical ventilation, and radiographic extent were not available for standardized group-wise analysis. Detailed standardized information on TMP-SMX exposure was unavailable. Although the interval from TMP-SMX initiation to caspofungin initiation was available, caspofungin treatment duration and the clinical rationale for its initiation were not documented, limiting assessment of whether treatment duration and indication influenced the outcomes. We therefore could not reliably distinguish early combination therapy from later salvage therapy. Third, the limited number of poor-outcome events may have contributed to imprecise and unstable multivariable estimates. The wide confidence interval for caspofungin combination therapy also limits the precision of the treatment estimate. Finally, adverse drug reactions and long-term outcomes were not systematically assessed. Thus, the absence of a statistically significant association does not exclude a potential benefit of adjunctive caspofungin in selected subgroups. Prospective multicenter studies are needed to confirm these findings.

Conclusion

In conclusion, in this retrospective cohort, no statistically significant association was detected between TMP-SMX plus adjunctive caspofungin and poor outcomes in patients with moderate-to-severe HIV-associated PJP. In the primary adjusted analysis, lower PaO2 on room air and higher CRP were associated with poor outcome. These exploratory associations may reflect oxygenation impairment and inflammatory burden, but do not establish definitive prognostic factors or identify patients likely to benefit from adjunctive caspofungin. Larger prospective multicenter studies, and randomized trials where feasible, are needed to confirm these findings and clarify the role of adjunctive caspofungin in selected patient populations.

Funding Statement

This study was funded by the National Science and Technology Major Project of China during the 13th Five-Year Plan period (2018ZX10302104) and the Beijing Research Ward Excellence Program (BRWEP2024W042180101). The funders had no role in the study design, data collection, analysis, interpretation, manuscript preparation, or publication.

Abbreviations

A-aDO2, alveolar-arterial oxygen tension gradient; ALT, alanine aminotransferase; aOR, adjusted odds ratio; ART, antiretroviral therapy; AST, aspartate aminotransferase; AUC, area under the receiver operating characteristic curve; CI, confidence interval; CRP, C-reactive protein; DHHS, Department of Health and Human Services; ESR, erythrocyte sedimentation rate; HIV, human immunodeficiency virus; ICU, intensive care unit; IPTW, inverse probability of treatment weightingLDH, lactate dehydrogenase; OR, odds ratio; PaO2, arterial partial pressure of oxygen; PCT, procalcitonin; PJP, Pneumocystis jirovecii pneumonia; TMP-SMX, trimethoprim-sulfamethoxazole; VIF, variance inflation factor.

Data Sharing Statement

The de-identified individual-level data analyzed in this study are not publicly available because of patient privacy, ethical, and institutional restrictions. Data may be made available by the corresponding author upon reasonable request, subject to approval by the relevant institutional review board and applicable data-sharing requirements.

Ethics Approval and Informed Consent

This study was conducted in accordance with the principles of the Declaration of Helsinki and its subsequent amendments. The study protocol was approved by the Ethics Committee of Beijing Youan Hospital (approval number: LL-2026-132-K). The requirement for written informed consent was waived by the Ethics Committee of Beijing Youan Hospital due to the retrospective nature of the study and the use of anonymized data collected from electronic medical records.

Author Contributions

Yu Wang contributed to conceptualization, methodology, investigation, writing-original draft, and visualization. Caopei Zheng contributed to investigation and writing-original draft. Yuqing Sun contributed to investigation and writing-original draft. Yulin Zhang contributed to conceptualization, supervision, project administration, funding acquisition, and writing-review and editing. All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

Disclosure

The authors report no conflicts of interest in this work.

References

  • 1.McDonald EG, Afshar A, Assiri B, et al. Pneumocystis jirovecii pneumonia in people living with HIV: a review. Clin Microbiol Rev. 2024;37(1):e0010122. doi: 10.1128/cmr.00101-22 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Chagas OJ, Gonçalves FAR, Nagatomo PP, et al. Predictive models-assisted diagnosis of AIDS-associated Pneumocystis jirovecii pneumonia in the emergency room, based on clinical, laboratory, and radiological data. Sci Rep. 2024;14(1):11247. doi: 10.1038/s41598-024-61174-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Wang X, Liu L, Wang W, et al. Mortality risk prediction model in AIDS patients with pneumocystis pneumonia in China. Front Cell Infect Microbiol. 2024;14(1485231). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Kamel T, Boulain T. Pneumocystis pneumonia in French intensive care units in 2013-2019: mortality and immunocompromised conditions. Ann Intensive Care. 2024;14(1):80. doi: 10.1186/s13613-024-01309-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Ewald H, Raatz H, Boscacci R, Furrer H, Bucher HC, Briel M. Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection. Cochrane Database Syst Rev. 2015;2015(4):Cd006150. doi: 10.1002/14651858.CD006150.pub2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.McDonald EG, Butler-Laporte G, Del Corpo O, et al. On the treatment of Pneumocystis jirovecii pneumonia: current practice based on outdated evidence. Open Forum Infect Dis. 2021;8(12):ofab545. doi: 10.1093/ofid/ofab545 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Wu Y, Shi H, Li W, et al. Analysis of mutations in Pneumocystis jirovecii dihydropteroate synthase and dihydropteroate reductase genes among non-HIV patients in China. Infect Drug Resist. 2024;17:5619–12. doi: 10.2147/IDR.S491478 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Xia H, Song J, Hu Y, Li L, Gao L, Ma P. Plasma IL-6 level predict the risk of in-hospital mortality in HIV-associated pneumocystis pneumonia. BMC Infect Dis. 2025;25(1):1823. doi: 10.1186/s12879-025-12188-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Butler-Laporte G, Smyth E, Amar-Zifkin A, Cheng MP, McDonald EG, Lee TC. Low-dose TMP-SMX in the treatment of Pneumocystis jirovecii pneumonia: a systematic review and meta-analysis. Open Forum Infect Dis. 2020;7(5):ofaa112. doi: 10.1093/ofid/ofaa112 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Yang JJ, Huang CH, Liu CE, et al. Multicenter study of trimethoprim/sulfamethoxazole-related hepatotoxicity: incidence and associated factors among HIV-infected patients treated for Pneumocystis jirovecii pneumonia. PLoS One. 2014;9(9):e106141. doi: 10.1371/journal.pone.0106141 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Maertens J, Raad I, Petrikkos G, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis. 2004;39(11):1563–1571. doi: 10.1086/423381 [DOI] [PubMed] [Google Scholar]
  • 12.Wang D, Guan L, Li X, Tong Z. A combined immune and inflammatory indicator predict the prognosis of severe Pneumocystis jirovecii pneumonia patients: a 12-year, retrospective, observational cohort. BMC Pulm Med. 2024;24(1):285. doi: 10.1186/s12890-024-03093-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Dickwella Widanage MC, Gautam I, Sarkar D, et al. Adaptative survival of Aspergillus fumigatus to echinocandins arises from cell wall remodeling beyond β-1,3-glucan synthesis inhibition. Nat Commun. 2024;15(1):6382. doi: 10.1038/s41467-024-50799-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Luraschi A, Richard S, Hauser PM. Site-directed mutagenesis of the 1,3-β-Glucan synthase catalytic subunit of Pneumocystis jirovecii and susceptibility assays suggest its sensitivity to caspofungin. Antimicrob Agents Chemother. 2018;62(12). doi: 10.1128/AAC.01159-18 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Qi H, Dong D, Liu N, Xu Y, Qi M, Gu Q. Efficacy of initial caspofungin plus trimethoprim/sulfamethoxazole for severe PCP in patients without human immunodeficiency virus infection. BMC Infect Dis. 2023;23(1):409. doi: 10.1186/s12879-023-08372-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Tian Q, Si J, Jiang F, et al. Caspofungin combined with TMP/SMZ as a first-line therapy for moderate-to-severe PCP in patients with human immunodeficiency virus infection. HIV Med. 2021;22(4):307–313. doi: 10.1111/hiv.13013 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Huang Y, He X, Chen H, et al. No statistically apparent difference in antifungal effectiveness observed among trimethoprim/sulfamethoxazole plus clindamycin or caspofungin, and trimethoprim/sulfamethoxazole monotherapy in HIV-infected patients with moderate to severe pneumocystis pneumonia: results of an observational multicenter cohort study. Infect Dis Ther. 2022;11(1):543–557. doi: 10.1007/s40121-021-00586-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.CDC. About HIV. 2026. Available from: https://www.cdc.gov/hiv/about/index.html. Accessed October 26, 2026.
  • 19.National Institutes of Health. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents With HIV. 2026. Available from: https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/pneumocystis?view=full. Accessed October 26, 2026.
  • 20.Giacobbe DR, Dettori S, Di Pilato V, et al. Pneumocystis jirovecii pneumonia in intensive care units: a multicenter study by ESGCIP and EFISG. Crit Care. 2023;27(1):323. doi: 10.1186/s13054-023-04608-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Lee WS, Hsueh PR, Hsieh TC, Chen FL, Ou TY, Jean SS. Caspofungin salvage therapy in Pneumocystis jirovecii pneumonia. J Microbiol Immunol Infect. 2017;50(4):547–548. doi: 10.1016/j.jmii.2016.03.008 [DOI] [PubMed] [Google Scholar]
  • 22.Walzer PD, Evans HE, Copas AJ, Edwards SG, Grant AD, Miller RF. Early predictors of mortality from Pneumocystis jirovecii pneumonia in HIV-infected patients: 1985-2006. Clin Infect Dis. 2008;46(4):625–633. doi: 10.1086/526778 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Sage EK, Noursadeghi M, Evans HE, et al. Prognostic value of C-reactive protein in HIV-infected patients with Pneumocystis jirovecii pneumonia. Int J STD AIDS. 2010;21(4):288–292. doi: 10.1258/ijsa.2010.009551 [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

The de-identified individual-level data analyzed in this study are not publicly available because of patient privacy, ethical, and institutional restrictions. Data may be made available by the corresponding author upon reasonable request, subject to approval by the relevant institutional review board and applicable data-sharing requirements.


Articles from Infection and Drug Resistance are provided here courtesy of Dove Press

RESOURCES